Josef Finsterer1. 1. Neurology & Neurophysiology Center, Vienna, Austria.
Abstract
INTRODUCTION: There is increasing evidence that vaccinations against the severe acquired respiratory syndrome coronavirus type-2 (SARS-CoV-2) virus can be followed by venous sinus thrombosis (VST). Here we report on three patients who developed VST shortly after SARS-CoV-2 vaccinations. CASE SERIES: An 80-year-old male, a 58-year-old male, and a 34-year-old female developed VST 14 to 24 days after the first dose of an mRNA-based SARS-CoV-2 vaccine. All three patients profited from analgesics, heparinisation, and oral anticoagulation, but made only an incomplete recovery at the time of discharge. Arguments for a causal relationship are: VST was time-linked to vaccination in the three patients; VST was previously reported after SARS-CoV-2 vaccination; SARS-CoV-2 infections can be complicated by VST; and SARS-CoV-2 can be associated with hypercoagulability. The fact that no hypercoagulability occurred in a pilot study after SARS-CoV-2 vaccination and that there has been no evidence of an increased prevalence/incidence of VST after vaccination since the introduction of the SARS-CoV-2 vaccination speak against a causal relationship. CONCLUSIONS: SARS-CoV-2 vaccinations can occasionally be followed by a VST. There are more arguments for than against a causal relationship.
INTRODUCTION: There is increasing evidence that vaccinations against the severe acquired respiratory syndrome coronavirus type-2 (SARS-CoV-2) virus can be followed by venous sinus thrombosis (VST). Here we report on three patients who developed VST shortly after SARS-CoV-2 vaccinations. CASE SERIES: An 80-year-old male, a 58-year-old male, and a 34-year-old female developed VST 14 to 24 days after the first dose of an mRNA-based SARS-CoV-2 vaccine. All three patients profited from analgesics, heparinisation, and oral anticoagulation, but made only an incomplete recovery at the time of discharge. Arguments for a causal relationship are: VST was time-linked to vaccination in the three patients; VST was previously reported after SARS-CoV-2 vaccination; SARS-CoV-2 infections can be complicated by VST; and SARS-CoV-2 can be associated with hypercoagulability. The fact that no hypercoagulability occurred in a pilot study after SARS-CoV-2 vaccination and that there has been no evidence of an increased prevalence/incidence of VST after vaccination since the introduction of the SARS-CoV-2 vaccination speak against a causal relationship. CONCLUSIONS: SARS-CoV-2 vaccinations can occasionally be followed by a VST. There are more arguments for than against a causal relationship.
Authors: Chaitanya B Medicherla; Rachel A Pauley; Adam de Havenon; Shadi Yaghi; Koto Ishida; Jose L Torres Journal: J Neuroophthalmol Date: 2020-12 Impact factor: 3.042
Authors: Behnood Bikdeli; David Jiménez; Pablo Demelo-Rodriguez; Francisco Galeano-Valle; José Antonio Porras; Raquel Barba; Cihan Ay; Radovan Malý; Andrei Braester; Egidio Imbalzano; Vladimir Rosa; Ramón Lecumberri; Carmine Siniscalchi; Ángeles Fidalgo; Salvador Ortiz; Manuel Monreal Journal: Viruses Date: 2022-01-18 Impact factor: 5.048
Authors: Steven Kerr; Mark Joy; Fatemeh Torabi; Stuart Bedston; Ashley Akbari; Utkarsh Agrawal; Jillian Beggs; Declan Bradley; Antony Chuter; Annemarie B Docherty; David Ford; Richard Hobbs; Srinivasa Vittal Katikireddi; Emily Lowthian; Simon de Lusignan; Ronan Lyons; James Marple; Colin McCowan; Dylan McGagh; Jim McMenamin; Emily Moore; Josephine-L K Murray; Rhiannon K Owen; Jiafeng Pan; Lewis Ritchie; Syed Ahmar Shah; Ting Shi; Sarah Stock; Ruby S M Tsang; Eleftheria Vasileiou; Mark Woolhouse; Colin R Simpson; Chris Robertson; Aziz Sheikh Journal: PLoS Med Date: 2022-02-22 Impact factor: 11.613